AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02816502 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management Skill Building Program A
Description: Subject will meet with the instructor and other students in the group once a week and complete homework and track amount of practice during the week.
Study NCT02816502 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management Skill Building Program B
Description: Subject will meet with the instructor and other students in the group once a week and complete homework and track amount of practice during the week.
Study NCT02342249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VX-787 300 mg
Description: A oral dose of 300 mg VX-787 tablet will be administered over 5-6 days.
Study NCT01539278 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation alone / no intervention
Description: Patients are observed over time, no surgery is done, subjects complete QOL questionnaires at set intervals
Study NCT03909932 — intervention group
Intervention type: OTHER
Intervention: Observational study : no intervention
Description: Observational study : only exporting data
Study NCT03335956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125281, 40mg, fasted
Description: CORT125281 is supplied as capsules for oral dosing
Study NCT03335956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 25mg, fasted
Description: Challenge Agent, Dose and Route of Administration:~Standard release 25 mg tablets, orally administered
Study NCT03045185 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RET using Ciprofloxacin 100mg, and Metronidazole 100mg.
Description: First Treatment Visit: Tooth isolation, access, pulp extirpation and root canal irrigation with 0.5% sodium hypochlorite. Canal negotiation, canal drying using paper points. Delivery of the Bi antibiotic paste (mixture of Bi antibiotic paste (Ciprofloxacin 100mg and Metronidazole 100mg with sterile water). Sealing tooth access with glass ionomer cement.~Second Treatment Visit: Tooth analgesia using plain local analgesics, isolatation and re-access as described above. Irrigation of root canal system using normal saline followed by paper point dying. Initiation of bleeding through insertion of a sterile 23-gauge needle with a length of 2 mm beyond the working length into the periapical tissues. Access sealed using Portland cement, followed by glass ionomer and then composite resin.
Study NCT01844492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The PARTNER Intervention
Description: The PARTNER intervention (PAiring Re-engineered ICU Teams with Nurse-driven Emotional Support and Relationship-building) consists of: 1) institution of a clinical pathway for family support overseen by ICU staff nurses; 2) advanced communication skills training for ICU staff nurses; 3) a multifaceted strategy to support implementation of the clinical pathway for family support.
Study NCT01844492 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ICU Usual Care Control
Description: The control group will receive usual care, in which the frequency and content of clinician-family communication is determined by the clinical team according to their usual practice. No study ICU has a protocolized approach to family communication and instead clinicians determine the timing and frequency of communication with families. All sites have palliative care services.
Study NCT03747588 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally-invasive pancreaticoduodenectomy
Description: Minimally-invasive pancreaticoduodenectomy for resection of pancreatic tumor
Study NCT03747588 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Open pancreaticoduodenectomy
Description: Open pancreaticoduodenectomy for resection of pancreatic tumor
Study NCT02654834 — intervention group
Intervention type: OTHER
Intervention: Exposure to nitrous oxide or other volatile anesthetics
Description: No intervention, but routine work-place exposure to volatile anesthetics
Study NCT02023281 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The experimental group will engage in mild-moderate level of exercise. This program will be structured and clinically supervised. Exercise will take place 2-3 days per week for a duration of 30-45 mins. for 12 weeks.
Study NCT03974425 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aflibercept Injection [Eylea]
Description: intravitreal injection of Aflibercept in resistant DME.
Study NCT02050516 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: micro-well group culture dish
Description: an embryo culture dish containing nine micro-wells in the middle.
Study NCT04553523 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrus Microstent
Description: Crescent-shaped nitinol device intended as a permanent implant to provide an outflow pathway for aqueous humor. The device is placed through the trabecular meshwork into Schlemm's canal immediately following placement of a monofocal IOL.
Study NCT04553523 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Cataract surgery performed using standard anesthesia and phacoemulsification techniques
Study NCT04553523 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monofocal IOL
Description: Commercially available monofocal intraocular lens as determined by the investigator
Study NCT00581035 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar and Meningitec
Description: 1 dose of Prevenar at 2,3.5,6 and 12 months and 1 dose of Meningitec at 2,6 and 12 months
Study NCT00581035 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar
Description: 1 dose at 2,3.5,6 and 12 months
Study NCT00581035 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningitec
Description: 1 dose at 2,6 and 12 months
Study NCT01942018 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: POEM
Description: Patients will receive Per oral endoscopic myotomy (POEM) for symptomatic gastroesophageal junction outflow obstruction (EGOO)
Study NCT02035670 — intervention group
Intervention type: OTHER
Intervention: Two-step diagnostic strategy
Description: The first step is to differentiate FUO according to the onset of disease and invasive pathogens. Apart from collecting detailed present medical history and careful physical examination, it focuses on seeking the clues of bacterial invasion two weeks before the fever onset from five aspects.To finish this part, the doctor needs to ask for informations following a list we already made, which covers more than forty definite items. If some of these items were proved existed, result of first step would be positive.~The second step is calculating the integral score of inflammatory biomarkers and vital diagnostic clues, WBC\& N, ESR, CRP, LDH, SF, ANCA, ANA, RF, PCT and T-Spot, as well as the clinical findings were included in this integrating system.The results of these items will be recorded and calculated with certain interval of time. If the score were more than nine, this part would be considered. positive.
Study NCT03373708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 100mg/m2
Study NCT03373708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600mg/m2
Study NCT03373708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m2(TC), 100mg/m2(EC-T)
Study NCT02050516 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: micro-well group culture dish
Description: an embryo culture dish containing nine micro-wells in the middle.
Study NCT01669226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEip (weekly) and TCiv
Description: IP: cisplatin 50mg/m2 and etoposide 100mg/m2, weekly, 4 times; 14 days later IV: paclitaxel 175mg/m2 plus carboplatin AUC 5 or docetaxel 60-75mg/m2 plus carboplatin AUC 5
Study NCT03373708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin acetate
Description: 3.6mg every month
Study NCT03373708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: 10mg twice daily oral
Study NCT03373708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5mg every daily oral
Study NCT01669226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TCiv
Description: IV: paclitaxel 175mg/m2 plus carboplatin AUC 5 or docetaxel 60-75mg/m2 plus carboplatin AUC 5
Study NCT03335956 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone 25mg, fasted
Description: Challenge Agent, Dose and Route of Administration:~Standard release 25 mg tablets, orally administered
Study NCT03335956 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule, fasted
Description: Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered
Study NCT03335956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15mg Tablet
Description: Probe Substrate, Dose and Route of Administration:~15 Mg tablet, orally administered
Study NCT03217656 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT00724932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Participants will receive an intravenous (i.v.) single bolus dose of 0.6 mg.kg-1 rocuronium. After this dose, maintenance doses of 0.1-0.2 mg.kg-1 rocuronium may be given.
Study NCT03335956 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pioglitazone 15mg Tablet
Description: Probe Substrate, Dose and Route of Administration:~15 Mg tablet, orally administered
Study NCT03335956 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule, fed
Description: Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered
Study NCT03335956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 25mg, fed
Description: Challenge Agent, Dose and Route of Administration:~Standard release 25 mg tablets, orally administered
Study NCT03335956 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone 25mg, fed
Description: Challenge Agent, Dose and Route of Administration:~Standard release 25 mg tablets, orally administered
Study NCT03335956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125281, 120mg, fasted
Description: CORT125281 is supplied as capsules for oral dosing
Study NCT03335956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125281, 360mg, fasted
Description: CORT125281 is supplied as capsules for oral dosing
Study NCT00226018 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hand Adapter (Organon, Oss, the Netherlands)
Description: Randomization of acceleromyography with or without Hand Adapter to dominant or non-dominant arm. Contralateral neuromuscular transmission is measured with mechanomyography (The gold standard of neuromuscular monitoring)
Study NCT03335956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125281, 720mg, fasted
Description: CORT125281 is supplied as capsules for oral dosing
Study NCT03335956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125281, 360mg, fed
Description: CORT125281 is supplied as capsules for oral dosing
Study NCT03335956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125281, 360mg
Description: CORT125281 is supplied as capsules for oral dosing twice, 12 hours apart, fasted (morning) and after evening meal
Study NCT02342249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VX-787 600 mg
Description: A oral dose of VX-787 600 mg (formulated as 2\*300 mg tablets) will be administered over 5-6 days.
Study NCT02342249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir 75 mg
Description: A oral dose of 75 mg Oseltamivir capsule will be administered over 5-6 days.
Study NCT02342249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will receive matching placebo of Oseltamivir
Study NCT02342249 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive matching placebo of Oseltamivir
Study NCT03335956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125281, 120mg
Description: CORT125281 is supplied as capsules for oral dosing once daily
Study NCT03335956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125281, 180mg
Description: CORT125281 is supplied as capsules for oral dosing twice daily
Study NCT03335956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125281, 240mg
Description: CORT125281 is supplied as capsules for oral dosing twice daily
Study NCT03335956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125281, 360mg
Description: CORT125281 is supplied as capsules for oral dosing once daily
Study NCT03335956 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered twice, 12 hours apart, fasted (morning) and after evening meal
Study NCT03335956 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered, twice daily
Study NCT03335956 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered, once daily
Study NCT00847938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neostigmine
Description: 0.04 mg/kg IV bolus, injection when the of train of four is > or = to 40 %
Study NCT00847938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neostigmine
Description: 0.02 mg/kg IV bolus, injection when the of train of four is > or = to 40 %
Study NCT00847938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neostigmine
Description: 0.01 mg/kg IV bolus, injection when the of train of four is > or = to 40 %
Study NCT04678011 — intervention group
Intervention type: PROCEDURE
Intervention: Personalized surveillance and intervention protocol
Description: This study uses one arm. Participants will undergo endoscopic surveillance with intervals between 6 months and 2 years, depending on severity of polyposis and performed endoscopic interventions.
Study NCT03424889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylometazoline
Description: Nasal administration of Xylometazoline
Study NCT03424889 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Nasal administration of 0.9% Saline
Study NCT01827930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate 600 MG Oral Tablet
Description: Imatinib Mesylate for CP CML
Study NCT01827930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib Mesylate 400 MG Oral Tablet
Description: Imatinib Mesylate for CP CML
Study NCT01827930 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Imatinib Mesylate
Description: Imatinib Mesylate for CP CML
Study NCT00413335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone
Description: 2mg to begin then 4mg, twice daily for 4 months
Study NCT00413335 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subject receives placebo.
Study NCT00253318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 40 mg/m\^2 IV over 1 hour on Day 1.
Study NCT00253318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: 30 mg orally on Days 1 and 8.
Study NCT00253318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 8 mg orally twice daily for 3 days, starting 24 hours prior to the administration of Docetaxel.
Study NCT00545987 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TriGrid™ Delivery System
Description: Subjects will be administered the study drug using Ichor Medical Systems' intramuscular TriGrid™ delivery device.
Study NCT00545987 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional intramuscular injection
Description: administration of an HIV-1 vaccine encoding the gag, env, pol, nef, and tat antigens (ADVAX)by conventional intramuscular injection
Study NCT03434704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conditioning treatment Thiotepa-Treosulfan-Fludarabine
Description: Thiotepa iv 5 mg/kg/bid (total dose TD 10 mg/kg) day -3,-2; Treosulfan iv 14g/mq/day (TD 42 g/mq) as a single daily dose day -6, -5, -4; Fludarabine iv 30 mg/m2 (TD 150 mg/m2) day -6, -5, -4, -3, -2. Thiotepa TD 5 mg/kg and treosulfan TD 36 g/mq dose reduction according to age > 65 years.
Study NCT03434704 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PBSC graft
Description: (target 4-8 × 106 CD34+ cells/kg patient body weight)
Study NCT03434704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GvHD prophylaxis
Description: Sirolimus orally, monitored two times a week to maintain a target therapeutic plasma level of 8-15 ng/ml from day +5.~Mycophenolate 15 mg/kg bid i.v. or per os day +5 through +28. Cyclophosphamide 50 mg/kg i.v. day +3+4. Mesna: >80% of the cyclophosphamide dose in 3 divided doses from day +3 daily through day +5.
Study NCT03434704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primary antifungal prophylaxis
Description: Posaconazole delayed-release tablet \[available in 100 mg tablets\]: 300 mg twice daily on the first day followed by a maintenance dose of 300 mg once a day, starting on the day 0 to day 85.
Study NCT01889628 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Liquid-based Nutritional Formulae and liquid glucose
Study NCT02905942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: PEG-rhG-CSF was given day +1 after autologous stem cell transplantation with a dose of 100μg/kg(bw).For patients more than 45kg, 6mg was suggested.
Study NCT02905942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhG-CSF
Description: rhG-CSF was given day +1 after transplantation with a dose of 5μg/kg once per day
Study NCT00921882 — intervention group
Intervention type: PROCEDURE
Intervention: Oral glucose tolerance test
Description: Subjects will have the Oral glucose tolerance test 48 hours post-partum and the same test 8 weeks post-partum.
Study NCT01427283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone/Naloxone controlled-release
Description: Oxycodone/Naloxone controlled-release tablets (10/5 - 40/20 mg) taken orally every 12 hours
Study NCT01427283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone HCl controlled-release
Description: Oxycodone HCl controlled-release tablets (10 - 40 mg) taken orally every 12 hours
Study NCT01427283 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets to match OXN or OXY taken orally every 12 hours
Study NCT02483104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: veliparib
Description: Veliparib will be given orally, twice daily on Days 1-21, every 21 days.
Study NCT00226018 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT00652028 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine, midazolam; fentanyl
Description: Dexmedetomidine for sedation; midazolam for rescue sedation according to label; fentanyl for rescue pain according to the label
Study NCT02483104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin will be administered on Day 1 of each cycle, intravenously.
Study NCT02483104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel will be administered on Days 1, 8, 15 of each cycle, intravenously.
Study NCT01974986 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water with flavoring and non-nutritive sweetener.
Description: A volume of fluid (water) was given after exercise to return each subject's body mass (to euhydration).
Study NCT01974986 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Na low-CHO beverage
Description: A volume of fluid (high-Na, low-CHO) was given after exercise to return each subject's body mass (to euhydration).
Study NCT01974986 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Na high-CHO beverage
Description: A volume of fluid (low-Na, high-CHO) was given after exercise to return each subject's body mass (to euhydration).
Study NCT01221688 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Axillar Sentinel lymph node biopsy
Description: Group 2 : Patients without proven axillary involved nodes will undergo SLNB and a complete axillary level I-II lymphadenectomy only in the case of detection failure or involved SLN and a SLNB alone in the others cases. Patients of this last group will be followed 5 years in order to evaluate the risk of axillary relapse without lymphadenectomy.
Study NCT01221688 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SLNB and complete level I-II axillary lymphadenectomy
Description: group 1 : patients with proven involved axillary nodes will undergo SLNB and complete level I-II axillary lymphadenectomy.
Study NCT02451436 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep and Media Use Intervention
Study NCT02451436 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Study Skills Control Group